Equities Analysts Offer Predictions for INKT FY2029 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Investment analysts at HC Wainwright issued their FY2029 EPS estimates for shares of MiNK Therapeutics in a research report issued to clients and investors on Tuesday, February 25th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.02) per share for the year. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share.

Separately, Robert W. Baird dropped their price target on MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th.

MiNK Therapeutics Trading Down 0.6 %

Shares of INKT stock opened at $9.26 on Wednesday. MiNK Therapeutics has a 12-month low of $4.56 and a 12-month high of $19.00. The business’s fifty day simple moving average is $8.47 and its 200-day simple moving average is $7.74. The company has a market cap of $36.69 million, a PE ratio of -2.37 and a beta of 0.17.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.